Vontobel Holding’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Vontobel Holding’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,827	Closed	-$283K	–	1118
2023 Q3	$283K	Hold	25,827	–	–	﹤0.01%	906
2023 Q2	$334K	Buy	25,827 +9,146	+55%	+$120K	﹤0.01%	898
2023 Q1	$200K	Hold	16,681	–	–	﹤0.01%	987
2022 Q4	$229K	Buy	+16,681	New	+$244K	﹤0.01%	956

Other funds holding CNCR

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vontobel Holding's CNCR Position: Q4 2023 in Review

Vontobel Holding sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2023, closing a stake of 25,827 shares — an estimated $283K sold.

Vontobel Holding first reported a position in CNCR in Q4 2022 and held it in 4 quarters. The position peaked at $334K in Q2 2023. 13 funds tracked by Wall St. Rank hold CNCR as of Q4 2023.

Vontobel Holding reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2023 after selling out during the quarter.
Vontobel Holding sold 25,827 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2023, an estimated $283K.
Vontobel Holding first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2022 and held it in 4 quarters.
Vontobel Holding's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $334K in Q2 2023.
13 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2023.

Based on Vontobel Holding's 13F filing for Q4 2023, filed 30 Jan 2024.